Treatment of plasma cell dyscrasias with lenalidomide

M. A. Dimopoulos, E. Kastritis, S Vincent Rajkumar

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Lenalidomide is an immunomodulatory drug, structurally related to thalidomide, with pleiotropic activity including antiangiogenic and antineoplastic properties. It is the product of advances in our understanding of the biology of myeloma cells, their interactions with the microenvironment and of the underlying molecular pathways. In preclinical and clinical studies, lenalidomide was more potent and less toxic than thalidomide. Subsequent phase II and III studies confirmed the activity of lenalidomide either as a single agent or in combination with dexamethasone in relapsed or refractory myeloma patients, whereas combinations with chemotherapy induce high response rates and durable remissions. Lenalidomide has been used successfully as an upfront treatment either with high or low dose dexamethasone or with melphalan and prednisone, resulting in high overall response and complete response rates and excellent 1-year survival. Lenalidomide causes less neuropathy than thalidomide; however, the risk of thromboembolism is high, especially in patients treated with lenalidomide and steroids. In this review, we summarize the mechanisms of action, toxicity and clinical activity, and the current role of lenalidomide in patients with multiple myeloma or other related plasma cell disorders.

Original languageEnglish (US)
Pages (from-to)1343-1353
Number of pages11
JournalLeukemia
Volume22
Issue number7
DOIs
StatePublished - Jul 2008

Fingerprint

Paraproteinemias
Thalidomide
Dexamethasone
Therapeutics
Melphalan
Poisons
Thromboembolism
Prednisone
Plasma Cells
lenalidomide
Combination Drug Therapy
Multiple Myeloma
Cell Communication
Antineoplastic Agents
Steroids
Survival
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Hematology
  • Cancer Research

Cite this

Treatment of plasma cell dyscrasias with lenalidomide. / Dimopoulos, M. A.; Kastritis, E.; Rajkumar, S Vincent.

In: Leukemia, Vol. 22, No. 7, 07.2008, p. 1343-1353.

Research output: Contribution to journalArticle

Dimopoulos, M. A. ; Kastritis, E. ; Rajkumar, S Vincent. / Treatment of plasma cell dyscrasias with lenalidomide. In: Leukemia. 2008 ; Vol. 22, No. 7. pp. 1343-1353.
@article{408aa950faf84295a5936cd3a8682654,
title = "Treatment of plasma cell dyscrasias with lenalidomide",
abstract = "Lenalidomide is an immunomodulatory drug, structurally related to thalidomide, with pleiotropic activity including antiangiogenic and antineoplastic properties. It is the product of advances in our understanding of the biology of myeloma cells, their interactions with the microenvironment and of the underlying molecular pathways. In preclinical and clinical studies, lenalidomide was more potent and less toxic than thalidomide. Subsequent phase II and III studies confirmed the activity of lenalidomide either as a single agent or in combination with dexamethasone in relapsed or refractory myeloma patients, whereas combinations with chemotherapy induce high response rates and durable remissions. Lenalidomide has been used successfully as an upfront treatment either with high or low dose dexamethasone or with melphalan and prednisone, resulting in high overall response and complete response rates and excellent 1-year survival. Lenalidomide causes less neuropathy than thalidomide; however, the risk of thromboembolism is high, especially in patients treated with lenalidomide and steroids. In this review, we summarize the mechanisms of action, toxicity and clinical activity, and the current role of lenalidomide in patients with multiple myeloma or other related plasma cell disorders.",
author = "Dimopoulos, {M. A.} and E. Kastritis and Rajkumar, {S Vincent}",
year = "2008",
month = "7",
doi = "10.1038/leu.2008.123",
language = "English (US)",
volume = "22",
pages = "1343--1353",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - Treatment of plasma cell dyscrasias with lenalidomide

AU - Dimopoulos, M. A.

AU - Kastritis, E.

AU - Rajkumar, S Vincent

PY - 2008/7

Y1 - 2008/7

N2 - Lenalidomide is an immunomodulatory drug, structurally related to thalidomide, with pleiotropic activity including antiangiogenic and antineoplastic properties. It is the product of advances in our understanding of the biology of myeloma cells, their interactions with the microenvironment and of the underlying molecular pathways. In preclinical and clinical studies, lenalidomide was more potent and less toxic than thalidomide. Subsequent phase II and III studies confirmed the activity of lenalidomide either as a single agent or in combination with dexamethasone in relapsed or refractory myeloma patients, whereas combinations with chemotherapy induce high response rates and durable remissions. Lenalidomide has been used successfully as an upfront treatment either with high or low dose dexamethasone or with melphalan and prednisone, resulting in high overall response and complete response rates and excellent 1-year survival. Lenalidomide causes less neuropathy than thalidomide; however, the risk of thromboembolism is high, especially in patients treated with lenalidomide and steroids. In this review, we summarize the mechanisms of action, toxicity and clinical activity, and the current role of lenalidomide in patients with multiple myeloma or other related plasma cell disorders.

AB - Lenalidomide is an immunomodulatory drug, structurally related to thalidomide, with pleiotropic activity including antiangiogenic and antineoplastic properties. It is the product of advances in our understanding of the biology of myeloma cells, their interactions with the microenvironment and of the underlying molecular pathways. In preclinical and clinical studies, lenalidomide was more potent and less toxic than thalidomide. Subsequent phase II and III studies confirmed the activity of lenalidomide either as a single agent or in combination with dexamethasone in relapsed or refractory myeloma patients, whereas combinations with chemotherapy induce high response rates and durable remissions. Lenalidomide has been used successfully as an upfront treatment either with high or low dose dexamethasone or with melphalan and prednisone, resulting in high overall response and complete response rates and excellent 1-year survival. Lenalidomide causes less neuropathy than thalidomide; however, the risk of thromboembolism is high, especially in patients treated with lenalidomide and steroids. In this review, we summarize the mechanisms of action, toxicity and clinical activity, and the current role of lenalidomide in patients with multiple myeloma or other related plasma cell disorders.

UR - http://www.scopus.com/inward/record.url?scp=47649104483&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=47649104483&partnerID=8YFLogxK

U2 - 10.1038/leu.2008.123

DO - 10.1038/leu.2008.123

M3 - Article

VL - 22

SP - 1343

EP - 1353

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 7

ER -